190 related articles for article (PubMed ID: 21665249)
1. Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer.
De Stefano I; Zannoni GF; Prisco MG; Fagotti A; Tortorella L; Vizzielli G; Mencaglia L; Scambia G; Gallo D
Gynecol Oncol; 2011 Sep; 122(3):573-9. PubMed ID: 21665249
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of the estrogen receptor beta (ERβ) isoforms ERβ1, ERβ2, and ERβ5 in advanced serous ovarian cancer.
Ciucci A; Zannoni GF; Travaglia D; Petrillo M; Scambia G; Gallo D
Gynecol Oncol; 2014 Feb; 132(2):351-9. PubMed ID: 24378878
[TBL] [Abstract][Full Text] [Related]
3. Hormone receptor expression profile of low-grade serous ovarian cancers.
Buttarelli M; Mascilini F; Zannoni GF; Ciucci A; Martinelli E; Filippetti F; Scambia G; Ferrandina G; Gallo D
Gynecol Oncol; 2017 May; 145(2):352-360. PubMed ID: 28228232
[TBL] [Abstract][Full Text] [Related]
4. Hormone receptors as a marker of poor survival in epithelial ovarian cancer.
van Kruchten M; van der Marel P; de Munck L; Hollema H; Arts H; Timmer-Bosscha H; de Vries E; Hospers G; Reyners A
Gynecol Oncol; 2015 Sep; 138(3):634-9. PubMed ID: 26115976
[TBL] [Abstract][Full Text] [Related]
5. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
Zhao XD; Zhang Y; He SR; Yang L
Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
[TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
[TBL] [Abstract][Full Text] [Related]
7. Expression of estrogen-responsive finger protein (Efp) is associated with advanced disease in human epithelial ovarian cancer.
Sakuma M; Akahira J; Suzuki T; Inoue S; Ito K; Moriya T; Sasano H; Okamura K; Yaegashi N
Gynecol Oncol; 2005 Dec; 99(3):664-70. PubMed ID: 16140366
[TBL] [Abstract][Full Text] [Related]
8. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
[TBL] [Abstract][Full Text] [Related]
9. Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis.
Chan KKL; Siu MKY; Jiang YX; Wang JJ; Wang Y; Leung THY; Liu SS; Cheung ANY; Ngan HYS
BMC Cancer; 2017 Aug; 17(1):606. PubMed ID: 28859612
[TBL] [Abstract][Full Text] [Related]
10. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
[TBL] [Abstract][Full Text] [Related]
11. Retinoid receptor alpha and Beta expression in serous ovarian tumors.
Daponte A; Kostopoulou E; Papandreou CN; Chiotoglou I; Voutsadakis I; Vanakara P; Minas M; Nakou M; Kallitsaris A; Kollia P; Koukoulis G; Messinis IE
Oncology; 2007; 73(1-2):81-9. PubMed ID: 18334854
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
[TBL] [Abstract][Full Text] [Related]
13. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
[TBL] [Abstract][Full Text] [Related]
14. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.
Saglam O; Xiong Y; Marchion DC; Strosberg C; Wenham RM; Johnson JJ; Saeed-Vafa D; Cubitt C; Hakam A; Magliocco AM
Cancer Control; 2017 Jan; 24(1):89-95. PubMed ID: 28178720
[TBL] [Abstract][Full Text] [Related]
15. Initial activation status of the antioxidant response determines sensitivity to carboplatin/paclitaxel treatment of ovarian cancer.
Pons DG; Sastre-Serra J; Nadal-Serrano M; Oliver A; García-Bonafé M; Bover I; Roca P; Oliver J
Anticancer Res; 2012 Nov; 32(11):4723-8. PubMed ID: 23155235
[TBL] [Abstract][Full Text] [Related]
16. The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.
Aust S; Horak P; Pils D; Pils S; Grimm C; Horvat R; Tong D; Schmid B; Speiser P; Reinthaller A; Polterauer S
BMC Cancer; 2013 Mar; 13():115. PubMed ID: 23497172
[TBL] [Abstract][Full Text] [Related]
17. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor β is associated with expression of cancer associated genes and survival in ovarian cancer.
Schüler-Toprak S; Weber F; Skrzypczak M; Ortmann O; Treeck O
BMC Cancer; 2018 Oct; 18(1):981. PubMed ID: 30326857
[TBL] [Abstract][Full Text] [Related]
19. [Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer].
Zhao D; Wu LY; Wang XB; Li XG; Li M; Li YF; Tian HM; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):368-72. PubMed ID: 20723436
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression and prognostic significance of oestrogen receptor-alpha, oestrogen receptor-beta, and progesterone receptor in stage 1 adult-type granulosa cell tumour of the ovary.
Hutton SM; Webster LR; Nielsen S; Leung Y; Stewart CJ
Pathology; 2012 Dec; 44(7):611-6. PubMed ID: 23149378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
